Literature DB >> 30652552

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

Laurent Dercle1, Dana E Connors1, Ying Tang1, Stacey J Adam1, Mithat Gönen1, Patrick Hilden1, Sanja Karovic1, Michael Maitland1, Chaya S Moskowitz1, Gary Kelloff1, Binsheng Zhao1, Geoffrey R Oxnard1, Lawrence H Schwartz1.   

Abstract

PURPOSE: To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors. PATIENTS AND METHODS: The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non-small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house-developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement.
RESULTS: The median duration of contracting with five sponsors was 12 months. Ten trials in 7,085 patients that covered 12 treatment regimens across 20 trial arms were collected. To date, four trials in 3,954 patients were analyzed. Source imaging data were transferred to the academic core from 97% of trial patients (n = 3,837). Tumor imaging measurements were extracted from 82% of transferred computed tomography scans (n = 3,162). Causes of extraction failure were nonmeasurable disease (n = 392), single imaging time point (n = 224), and secondary captured images (n = 59). Overall, clinically annotated imaging data were extracted in 79% of patients (n = 3,055), and the primary trial end point analysis in each trial remained representative of each original trial end point.
CONCLUSION: The sharing and analysis of source imaging data from large randomized trials is feasible and offer a rich and reusable, but largely untapped, resource for future research on novel trial-level response and progression imaging metrics.

Entities:  

Mesh:

Year:  2018        PMID: 30652552      PMCID: PMC6873999          DOI: 10.1200/CCI.17.00137

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  32 in total

1.  Pseudoprogression and Immune-Related Response in Solid Tumors.

Authors:  Victoria L Chiou; Mauricio Burotto
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

2.  Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.

Authors:  Geoffrey R Oxnard; Binsheng Zhao; Camelia S Sima; Michelle S Ginsberg; Leonard P James; Robert A Lefkowitz; Pingzhen Guo; Mark G Kris; Lawrence H Schwartz; Gregory J Riely
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

3.  Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.

Authors:  J Y Douillard; S Siena; J Cassidy; J Tabernero; R Burkes; M Barugel; Y Humblet; G Bodoky; D Cunningham; J Jassem; F Rivera; I Kocákova; P Ruff; M Błasińska-Morawiec; M Smakal; J L Canon; M Rother; K S Oliner; Y Tian; F Xu; R Sidhu
Journal:  Ann Oncol       Date:  2014-04-08       Impact factor: 32.976

4.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

5.  When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

Authors:  Geoffrey R Oxnard; Michael J Morris; F Stephen Hodi; Laurence H Baker; Mark G Kris; Alan P Venook; Lawrence H Schwartz
Journal:  J Natl Cancer Inst       Date:  2012-08-27       Impact factor: 13.506

6.  Segmentation of lung lesions on CT scans using watershed, active contours, and Markov random field.

Authors:  Yongqiang Tan; Lawrence H Schwartz; Binsheng Zhao
Journal:  Med Phys       Date:  2013-04       Impact factor: 4.071

7.  Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.

Authors:  Marc Peeters; Jean-Yves Douillard; Eric Van Cutsem; Salvatore Siena; Kathy Zhang; Richard Williams; Jeffrey Wiezorek
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

8.  Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Authors:  Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

9.  Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Authors:  C H Li; R R Bies; Y Wang; M R Sharma; S Karovic; L Werk; M J Edelman; A A Miller; E E Vokes; A Oto; M J Ratain; L H Schwartz; M L Maitland
Journal:  Clin Transl Sci       Date:  2016-01-21       Impact factor: 4.689

10.  A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology.

Authors:  Hao Yang; Lawrence H Schwartz; Binsheng Zhao
Journal:  Tomography       Date:  2016-12
View more
  4 in total

1.  Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.

Authors:  Laurent Dercle; Lin Lu; Lawrence H Schwartz; Min Qian; Sabine Tejpar; Peter Eggleton; Binsheng Zhao; Hubert Piessevaux
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

2.  Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.

Authors:  Firas S Ahmed; Laurent Dercle; Gregory V Goldmacher; Hao Yang; Dana Connors; Ying Tang; Sanja Karovic; Binsheng Zhao; Richard D Carvajal; Caroline Robert; Michael L Maitland; Geoffrey R Oxnard; Lawrence H Schwartz
Journal:  Eur Radiol       Date:  2020-09-30       Impact factor: 7.034

3.  Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging.

Authors:  Lin Lu; Laurent Dercle; Binsheng Zhao; Lawrence H Schwartz
Journal:  Nat Commun       Date:  2021-11-17       Impact factor: 14.919

4.  Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.

Authors:  Michael L Maitland; Julia Wilkerson; Sanja Karovic; Binsheng Zhao; Jessica Flynn; Mengxi Zhou; Patrick Hilden; Firas S Ahmed; Laurent Dercle; Chaya S Moskowitz; Ying Tang; Dana E Connors; Stacey J Adam; Gary Kelloff; Mithat Gonen; Tito Fojo; Lawrence H Schwartz; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 12.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.